Limits...
Cohort profile: golestan hepatitis B cohort study- a prospective long term study in northern iran ​.

Poustchi H, Katoonizadeh A, Ostovaneh MR, Moossavi S, Sharafkhah M, Esmaili S, Pourshams A, Mohamadkhani A, Besharat S, Merat S, Mohamadnejad M, George J, Malekzadeh R - Middle East J Dig Dis (2014)

Bottom Line: In 2008, a baseline measurement of HBV surface antigen (HBsAg) was performed on stored serum samples of all GCS participants.A sub-cohort of 3,505 individuals were found to be HBsAg positive and were enrolled in the Golestan HBCS.In 2011, all first degree relatives of HBsAg positive subjects including their children and spouses were invited for HBV serology screening and those who were positive for HBsAg were also included in the Golestan HBCS.

View Article: PubMed Central - HTML - PubMed

Affiliation: Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran university of Medical Sciences, Tehran, Iran.

ABSTRACT
Hepatitis B virus (HBV) infection is the most common cause of end stage liver disease in Iran and in Golestan province. Large-scale population-based prospective cohort studies with long term follow-up are the method of choice to accurately understand the natural course of HBV infection. To date, several studies of HBV epidemiology, natural history, progression to cirrhosis and association with HCC have been reported from other countries. However, few of these are prospective and fewer still are population-based. Moreover, the underlying molecular mechanisms and immunogenetic determinants of the outcome of HBV infection especially in low and middle income countries remains largely unknown. Therefore, the hepatitis B cohort study (HBCS), nested as part of the Golestan Cohort Study (GCS), Golestan, Iran was established in 2008 with the objective to prospectively investigate the natural course of chronic hepatitis B with reference to its epidemiology, viral/host genetic interactions, clinical features and outcome in the Middle East where genotype D HBV accounts for >90% of infections. In 2008, a baseline measurement of HBV surface antigen (HBsAg) was performed on stored serum samples of all GCS participants. A sub-cohort of 3,505 individuals were found to be HBsAg positive and were enrolled in the Golestan HBCS. In 2011, all first degree relatives of HBsAg positive subjects including their children and spouses were invited for HBV serology screening and those who were positive for HBsAg were also included in the Golestan HBCS.

No MeSH data available.


Related in: MedlinePlus

© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4208926&req=5

Mentions: Golestan HBCS is divided into three distinct phases (Figure 2). In phase I (enrolment in the GCS: 2004-2008), participants of the cohort were interviewed by well-trained and educated staff, examined by general practitioners and screened for CHB by measuring HBsAg. The participants were then contacted annually by telephone to ascertain major illnesses or mortality. In case of death, in addition to collection of all medical documents from the hospital or home including pathology and laboratory reports, a verbal autopsy was performed. The reliability of verbal autopsy in GCS has been previously established.24 In phase II (enrolment in Golestan HBCS and repeated measurements: 2008-2012), HBsAg positive individuals and their immediate family members (spouses and children) underwent blood sampling for (re)assessment of HBV infection in a central cohort clinic where they were re-interviewed using structured questionnaires. The questionnaires addressed different aspects including socio-demographic factors, general health and family medical history, quality of life information and risk factors for HBV infection. Immediate family members who were found to be HBsAg positive were enrolled in Golestan HBCS. All participants in Phase II were contacted by telephone for annual follow-up. All family members who tested negative for HBsAg were offered HBV vaccination. It is the intention of Golestan HBCS to annually follow all participants during phase III (2012-2022). Subjects who need treatment were introduced to a special HBV follow-up clinic at Atrak centre in Gonbad that is staffed by a visiting gastroenterologist.


Cohort profile: golestan hepatitis B cohort study- a prospective long term study in northern iran ​.

Poustchi H, Katoonizadeh A, Ostovaneh MR, Moossavi S, Sharafkhah M, Esmaili S, Pourshams A, Mohamadkhani A, Besharat S, Merat S, Mohamadnejad M, George J, Malekzadeh R - Middle East J Dig Dis (2014)

© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4208926&req=5

Mentions: Golestan HBCS is divided into three distinct phases (Figure 2). In phase I (enrolment in the GCS: 2004-2008), participants of the cohort were interviewed by well-trained and educated staff, examined by general practitioners and screened for CHB by measuring HBsAg. The participants were then contacted annually by telephone to ascertain major illnesses or mortality. In case of death, in addition to collection of all medical documents from the hospital or home including pathology and laboratory reports, a verbal autopsy was performed. The reliability of verbal autopsy in GCS has been previously established.24 In phase II (enrolment in Golestan HBCS and repeated measurements: 2008-2012), HBsAg positive individuals and their immediate family members (spouses and children) underwent blood sampling for (re)assessment of HBV infection in a central cohort clinic where they were re-interviewed using structured questionnaires. The questionnaires addressed different aspects including socio-demographic factors, general health and family medical history, quality of life information and risk factors for HBV infection. Immediate family members who were found to be HBsAg positive were enrolled in Golestan HBCS. All participants in Phase II were contacted by telephone for annual follow-up. All family members who tested negative for HBsAg were offered HBV vaccination. It is the intention of Golestan HBCS to annually follow all participants during phase III (2012-2022). Subjects who need treatment were introduced to a special HBV follow-up clinic at Atrak centre in Gonbad that is staffed by a visiting gastroenterologist.

Bottom Line: In 2008, a baseline measurement of HBV surface antigen (HBsAg) was performed on stored serum samples of all GCS participants.A sub-cohort of 3,505 individuals were found to be HBsAg positive and were enrolled in the Golestan HBCS.In 2011, all first degree relatives of HBsAg positive subjects including their children and spouses were invited for HBV serology screening and those who were positive for HBsAg were also included in the Golestan HBCS.

View Article: PubMed Central - HTML - PubMed

Affiliation: Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran university of Medical Sciences, Tehran, Iran.

ABSTRACT
Hepatitis B virus (HBV) infection is the most common cause of end stage liver disease in Iran and in Golestan province. Large-scale population-based prospective cohort studies with long term follow-up are the method of choice to accurately understand the natural course of HBV infection. To date, several studies of HBV epidemiology, natural history, progression to cirrhosis and association with HCC have been reported from other countries. However, few of these are prospective and fewer still are population-based. Moreover, the underlying molecular mechanisms and immunogenetic determinants of the outcome of HBV infection especially in low and middle income countries remains largely unknown. Therefore, the hepatitis B cohort study (HBCS), nested as part of the Golestan Cohort Study (GCS), Golestan, Iran was established in 2008 with the objective to prospectively investigate the natural course of chronic hepatitis B with reference to its epidemiology, viral/host genetic interactions, clinical features and outcome in the Middle East where genotype D HBV accounts for >90% of infections. In 2008, a baseline measurement of HBV surface antigen (HBsAg) was performed on stored serum samples of all GCS participants. A sub-cohort of 3,505 individuals were found to be HBsAg positive and were enrolled in the Golestan HBCS. In 2011, all first degree relatives of HBsAg positive subjects including their children and spouses were invited for HBV serology screening and those who were positive for HBsAg were also included in the Golestan HBCS.

No MeSH data available.


Related in: MedlinePlus